Belite Bio to present Phase 3 DRAGON tinlarebant results in Stargardt disease at SOG congress

BLTE•2026-08-21

Phase 3 DRAGON results to be presented in late August

Belite Bio flagged new Phase 3 DRAGON study results for tinlarebant in Stargardt disease; presentations are scheduled for late August 2026.

Management is positioning the readout as supportive of tinlarebant’s clinical profile in adolescent and adult patients, without disclosing detailed figures.

Investors will get the first public look at the data at the SOG congress on Aug. 27, followed by APVRS sessions on Aug. 30.

Belite Bio to present Phase 3 DRAGON tinlarebant results in Stargardt disease at SOG congress

Phase 3 DRAGON results to be presented in late August

Related News

Euro zone bond yields steady as inflation, fiscal worries remain in focus

Deere & Co <DE.N>: Bofa Global Research Raises Price Objective to $667.00 from $607.50

Pearl Diver Credit updates financial calendar with upcoming Q2 earnings release, conference call

Entera Bio files Form 3 for Chief Medical Officer Riccardo Paolo Camisasca

BJ's Wholesale Club rises on raised annual profit forecast